182 related articles for article (PubMed ID: 24602489)
1. Conjugation to a SMAC mimetic potentiates sigma-2 ligand induced tumor cell death in ovarian cancer.
Garg G; Vangveravong S; Zeng C; Collins L; Hornick M; Hashim Y; Piwnica-Worms D; Powell MA; Mutch DG; Mach RH; Hawkins WG; Spitzer D
Mol Cancer; 2014 Mar; 13():50. PubMed ID: 24602489
[TBL] [Abstract][Full Text] [Related]
2. Sigma-2 receptor ligand as a novel method for delivering a SMAC mimetic drug for treating ovarian cancer.
Zeng C; Vangveravong S; McDunn JE; Hawkins WG; Mach RH
Br J Cancer; 2013 Oct; 109(9):2368-77. PubMed ID: 24104966
[TBL] [Abstract][Full Text] [Related]
3. Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV-134.
Hashim YM; Spitzer D; Vangveravong S; Hornick MC; Garg G; Hornick JR; Goedegebuure P; Mach RH; Hawkins WG
Mol Oncol; 2014 Jul; 8(5):956-67. PubMed ID: 24731702
[TBL] [Abstract][Full Text] [Related]
4. The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer.
Hashim YM; Vangveravong S; Sankpal NV; Binder PS; Liu J; Goedegebuure SP; Mach RH; Spitzer D; Hawkins WG
J Exp Clin Cancer Res; 2017 Jan; 36(1):14. PubMed ID: 28095907
[TBL] [Abstract][Full Text] [Related]
5. The targeted SMAC mimetic SW IV-134 augments platinum-based chemotherapy in pre-clinical models of ovarian cancer.
Binder PS; Hashim YM; Cripe J; Buchanan T; Zamorano A; Vangveravong S; Mutch DG; Hawkins WG; Powell MA; Spitzer D
BMC Cancer; 2022 Mar; 22(1):263. PubMed ID: 35279106
[TBL] [Abstract][Full Text] [Related]
6. Design of small-molecule peptidic and nonpeptidic Smac mimetics.
Sun H; Nikolovska-Coleska Z; Yang CY; Qian D; Lu J; Qiu S; Bai L; Peng Y; Cai Q; Wang S
Acc Chem Res; 2008 Oct; 41(10):1264-77. PubMed ID: 18937395
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of a novel homodimeric SMAC mimetic in ovarian carcinoma.
Gatti L; De Cesare M; Ciusani E; Corna E; Arrighetti N; Cominetti D; Belvisi L; Potenza D; Moroni E; Vasile F; Lecis D; Delia D; Castiglioni V; Scanziani E; Seneci P; Zaffaroni N; Perego P
Mol Pharm; 2014 Jan; 11(1):283-93. PubMed ID: 24256025
[TBL] [Abstract][Full Text] [Related]
8. Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy.
Kashiwagi H; McDunn JE; Simon PO; Goedegebuure PS; Xu J; Jones L; Chang K; Johnston F; Trinkaus K; Hotchkiss RS; Mach RH; Hawkins WG
Mol Cancer; 2007 Jul; 6():48. PubMed ID: 17631687
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin sensitizes cancer cells to Smac mimetic via synergistic activation of the CYLD/RIPK1/FADD/caspase-8-dependent apoptosis.
Yang C; Ran Q; Zhou Y; Liu S; Zhao C; Yu X; Zhu F; Ji Y; Du Q; Yang T; Zhang W; He S
Apoptosis; 2020 Jun; 25(5-6):441-455. PubMed ID: 32418059
[TBL] [Abstract][Full Text] [Related]
10. Lysosomal membrane permeabilization is an early event in Sigma-2 receptor ligand mediated cell death in pancreatic cancer.
Hornick JR; Vangveravong S; Spitzer D; Abate C; Berardi F; Goedegebuure P; Mach RH; Hawkins WG
J Exp Clin Cancer Res; 2012 May; 31(1):41. PubMed ID: 22551149
[TBL] [Abstract][Full Text] [Related]
11. Smac peptide potentiates TRAIL- or paclitaxel-mediated ovarian cancer cell death in vitro and in vivo.
Mao HL; Pang Y; Zhang X; Yang F; Zheng J; Wang Y; Liu P
Oncol Rep; 2013 Feb; 29(2):515-22. PubMed ID: 23151974
[TBL] [Abstract][Full Text] [Related]
12. A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells.
Petrucci E; Pasquini L; Petronelli A; Saulle E; Mariani G; Riccioni R; Biffoni M; Ferretti G; Benedetti-Panici P; Cognetti F; Scambia G; Humphreys R; Peschle C; Testa U
Gynecol Oncol; 2007 May; 105(2):481-92. PubMed ID: 17292950
[TBL] [Abstract][Full Text] [Related]
13. Potent and selective small-molecule inhibitors of cIAP1/2 proteins reveal that the binding of Smac mimetics to XIAP BIR3 is not required for their effective induction of cell death in tumor cells.
Sun H; Lu J; Liu L; Yang CY; Wang S
ACS Chem Biol; 2014 Apr; 9(4):994-1002. PubMed ID: 24521431
[TBL] [Abstract][Full Text] [Related]
14. The novel drug candidate S2/IAPinh improves survival in models of pancreatic and ovarian cancer.
Hagi T; Vangveravong S; Takchi R; Gong Q; Goedegebuure SP; Tiriac H; Van Tine BA; Powell MA; Hawkins WG; Spitzer D
Sci Rep; 2024 Mar; 14(1):6373. PubMed ID: 38493257
[TBL] [Abstract][Full Text] [Related]
15. Smac mimetics increase cancer cell response to chemotherapeutics in a TNF-α-dependent manner.
Probst BL; Liu L; Ramesh V; Li L; Sun H; Minna JD; Wang L
Cell Death Differ; 2010 Oct; 17(10):1645-54. PubMed ID: 20431601
[TBL] [Abstract][Full Text] [Related]
16. Smac modulates chemosensitivity in head and neck cancer cells through the mitochondrial apoptotic pathway.
Sun Q; Zheng X; Zhang L; Yu J
Clin Cancer Res; 2011 Apr; 17(8):2361-72. PubMed ID: 21242120
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel second mitochondria-derived activator of caspase mimetics as selective inhibitor of apoptosis protein inhibitors.
Wang J; Li W
J Pharmacol Exp Ther; 2014 May; 349(2):319-29. PubMed ID: 24623800
[TBL] [Abstract][Full Text] [Related]
18. A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB.
Dai Y; Liu M; Tang W; Li Y; Lian J; Lawrence TS; Xu L
BMC Cancer; 2009 Nov; 9():392. PubMed ID: 19895686
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibitors and Smac mimetics cooperate to induce cell death in diffuse large B-cell lymphoma by stabilizing NOXA and triggering mitochondrial apoptosis.
Dietz A; Dalda N; Zielke S; Dittmann J; van Wijk SJL; Vogler M; Fulda S
Int J Cancer; 2020 Sep; 147(5):1485-1498. PubMed ID: 32170726
[TBL] [Abstract][Full Text] [Related]
20. Smac mimetic SM-164 potentiates APO2L/TRAIL- and doxorubicin-mediated anticancer activity in human hepatocellular carcinoma cells.
Zhang S; Li G; Zhao Y; Liu G; Wang Y; Ma X; Li D; Wu Y; Lu J
PLoS One; 2012; 7(12):e51461. PubMed ID: 23240027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
